The present invention relates to a new process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt. Further the present invention also relates to the use of the new crystal modifications for the treatment of gastrointestinal disorders pharmaceutical compositions containing them as well as the crystal modifications as such.

The present invention relates to a novel process for preparing a novel form of the (-)-enantiomer of 5-methoxy-2-ÄÄ(4-methoxy-35-dimethyl-2-pyridinyl)-methylÜsulfinylÜ-1H -benzimidazole i.e. S-omeprazole. More specifically it relates to a process for preparing trihydrate of magnesium salt of S-omeprazole. Furthermore the present invention also relates to new intermediates used in that process.

The present invention relates to a novel co-crystal of the compound of formula (I): wherein the co-former molecule is acetyl salicylic acid, to processes for the preparation of the co-crystal, to pharmaceutical compositions containing the co-crystal, to the use of such a co-crystal in the manufacture of a medicament for use in the prevention of arterial thrombotic complications in patients with coronary artery, cerebrovascular or peripheral vascular disease and to methods of treating such diseas...

The present invention relates to a new process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt. Further the present invention also relates to the use of the new crystal modifications for the treatment of gastrointestinal disorders pharmaceutical compositions containing them as well as the crystal modifications as such.

The present invention relates to compounds of formula (I) The compounds act via antagonism of the CCR2b receptor and may be used to treat inflammatory disease and/or neuropathic pain.

The present invention relates to compounds of formula (I) The compounds act via antagonism of the CCR2b receptor and may be used to treat inflammatory disease and/or neuropathic pain.